

LIONS EYE BANK OF CENTRAL TEXAS St. David's Medical Center 919 E. 32nd Street Austin, Texas 78705 Facility: 900 E. 30th St., Suite 214 Phone: 512.457.0638 or 800.977.3937 Fax: 512.457.0658 Email: lebct@io.com GLENN CRAIG President CHARLES PERKINS Ist Vice President RICHARDE, NIEMAN, MD Medical Director SAMUEL FULCHER, MD Regional Medical Director ROBERT L. ROCK, MD Corneal Consultant GEORGE CHIHORNE, JR., MD Corneal Consultant GARY R. RYLANDER, MD Corneal Consultant BESS BELIVEAUX, CEBT Executive Directo ASSOCIATION of AMERICA And member of the Eye Bank Association of Texas

Monday, December 13, 1999

Dockets Management Branch (HFA-305) Food and Drug Administration 9927 '99 DEC 23 P 1:1 4 5630 Fishers Lane, rm. 1061 Rockville, MD. 20852

Reference: Docket No. 97N-484S

To whom it may concern,

I have practiced in Texas as a corneal surgeon for a number of years and am distressed to hear that the Food and Drug Administration will be adding a series of questions regarding Creutzfeldt-Jakob disease (CJD) to medical screening standards for <u>all</u> donor corneas. This modification will significantly affect tissues currently being obtained via legislative consent.

Texas and the United States have greatly benefited by having available these young, healthy donor corneas recovered through the cooperative efforts of medical examiners. Medical examiner laws have been instrumental in helping to eliminate the waiting lists of patients in need of sight restoring corneal transplantation; and, has successfully and safely provided donor corneal tissues (in Texas) since 1977. This important legislation provides 50%-60% of the donor corneal tissues for our community.

In checking with several neuropathologists and forensic pathologists, I have not been able to link one case of transmission of CJD via corneal transplant of tissues obtained from the forensic setting. Establishing this new screening criterion carries the potential, if not inevitable, loss of younger quality corneal tissues.

I appreciate the position that the FDA has taken to develop and maintain strict medical standards and screening devices to help ensure a safe supply of donor corneal tissues. However, with the annual incidence of CJD at one case per million population (with most cases being present in patients 60 years of age or older) and the calculated risk of a prion- infected corneal donor at .005%, imposing these screening steps which will terminate this important law is unnecessary.

There is a vital necessity for the support and continued utilization of this law within the corneal transplant community. I ask that you please reconsider your position on this important matter.

Sincerely,


Richard E. Nieman, MD

Medical Director

Lions Eye Bank of Central Texas

97N-4845

C 171



PRESORTED FIRST CLASS



Dockets Management Branch (HFA-305) Food and Drug Administration 5630 Fishers Lane, Km. 1061 Rockville, MD 20852

AUMP 20857

Tuddllankalakdanlllanllanllanndlalldlandall